142 results about "Overactive bladder" patented technology

Current treatment options for Overactive Bladder and Urinary Incontinence include exercise and behavioral modifications, pharmacological therapies, surgical intervention, and neuromodulation. Although each of these treatments is used in the treatment of individuals with these conditions, each has severe limitations. Building on the limitations of existing therapies, and with the distillation of lessons learned from the field of pulsed electric stimulation, the present invention employs Low Frequency Induction Therapy for the delivery of an effective, cost efficient, noninvasive alternative to available treatment options. The device of the present application allows for consistent, user-friendly modulation of the pudendal nerve and the sacral plexus, via pulsed electromagnetic stimulation of the posterior tibial nerve, on an outpatient basis. The device has two primary components: a programmable Logic Controller (LC), which generates the required current, and a Conductive Wrap (CW), through which the current is channeled in generating the pulsed electromagnetic fields.

Transcutaneous electrical and magnetic nerve stimulation devices and methods generate energy that is delivered noninvasively to selected nerve fibers within the patient to treat lower urinary tract disorders. The disorders comprise overactive bladder, urge incontinence, stress, incontinence, urge frequency, non-obstructive urinary retention and interstitial cystitis / painful bladder syndrome. In preferred embodiments, a posterior tibial nerve of a patient is stimulated non-invasively to treat bladder disorders.

A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and / or pain.

A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the α2δ calcium channel subunit.

An implantable urodynamic system includes an implantable first device deployable in a patient's bladder, an implantable second device deployable in a patient's vaginal canal, and a data acquisition and analysis module or processing unit external to the body of the patient. The first device includes a magnet and an inductive coil, and the second device includes a magnet, an inductive coil and a battery. When deployed in the patient's body, attraction between the magnets maintains the two devices in close proximity to one another to effect an inductive coupling between the coils so that the first device may be powered by the battery of the second device. The urodynamic system is intended to facilitate measurement, collection, and wireless transmission of real-time, or near real-time, data (bladder pressure, abdominal pressure, and temperature) from an ambulatory patient. This data is of value in diagnosing a number of abnormal bladder conditions, such as infection, overactive bladder, bladder spasms, and the like.

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and / or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.